Book a meeting
DO-BO

How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters? (Repost)

This is a repost of a popular episode of MAP, Market Access Podcast, from 15th of July 2023.

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?

In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with – clinical development, regulatory and payers.

Stay updated for upcoming webinars through LinkedIn, and take the chance to stay connected through subscribing with your favorite podcasting platform or directly listen on our website: MAP Podcasts 

Related

Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?

By

Stefan Walzer

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe […]

From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher?

By

Stefan Walzer

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They […]

Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali?

By

Stefan Walzer

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.  They explore why cost‑effectiveness thresholds are making market access […]